These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8985153)

  • 41. Studies on the primary sequence requirements for PKC-alpha, -beta 1 and -gamma peptide substrates.
    Marais RM; Nguyen O; Woodgett JR; Parker PJ
    FEBS Lett; 1990 Dec; 277(1-2):151-5. PubMed ID: 1702730
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acidic residues at the carboxyl terminus of p60c-src are required for regulation of tyrosine kinase activity and transformation.
    MacAuley A; Cooper JA
    New Biol; 1990 Sep; 2(9):828-40. PubMed ID: 1703788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis.
    Hansen K; Johnell M; Siegbahn A; Rorsman C; Engström U; Wernstedt C; Heldin CH; Rönnstrand L
    EMBO J; 1996 Oct; 15(19):5299-313. PubMed ID: 8895575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases.
    Han NM; Curley SA; Gallick GE
    Clin Cancer Res; 1996 Aug; 2(8):1397-404. PubMed ID: 9816313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In silico screening and biological evaluation of inhibitors of Src-SH3 domain interaction with a proline-rich ligand.
    Atatreh N; Stojkoski C; Smith P; Booker GW; Dive C; Frenkel AD; Freeman S; Bryce RA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1217-22. PubMed ID: 18083027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface.
    Lubman OY; Waksman G
    J Mol Biol; 2002 Feb; 316(2):291-304. PubMed ID: 11851339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploration of the sequence specificity of pp60c-src tyrosine kinase. Minimal peptide sequence required for maximal activity.
    Edison AM; Barker SC; Kassel DB; Luther MA; Knight WB
    J Biol Chem; 1995 Nov; 270(45):27112-5. PubMed ID: 7592964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hydrophobic D-amino acids in the design of peptide ligands for the pp60src SH2 domain.
    Plummer MS; Lunney EA; Para KS; Prasad JV; Shahripour A; Singh J; Stankovic CJ; Humblet C; Fergus JH; Marks JS; Sawyer TK
    Drug Des Discov; 1996 Apr; 13(3-4):75-81. PubMed ID: 8874045
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design of tetrapeptide ligands as inhibitors of the Src SH2 domain.
    Nam NH; Pitts RL; Sun G; Sardari S; Tiemo A; Xie M; Yan B; Parang K
    Bioorg Med Chem; 2004 Feb; 12(4):779-87. PubMed ID: 14759738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reusable amperometric biosensor for measuring protein tyrosine kinase activity.
    Wang CL; Wei LY; Yuan CJ; Hwang KC
    Anal Chem; 2012 Jan; 84(2):971-7. PubMed ID: 22208917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src.
    Gonfloni S; Weijland A; Kretzschmar J; Superti-Furga G
    Nat Struct Biol; 2000 Apr; 7(4):281-6. PubMed ID: 10742171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding.
    Nam NH; Ye G; Sun G; Parang K
    J Med Chem; 2004 Jun; 47(12):3131-41. PubMed ID: 15163193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mechanism of c-SRC activation in human melanocytes: elevated level of protein tyrosine phosphatase activity directed against the carboxy-terminal regulatory tyrosine.
    O'Connor TJ; Bjorge JD; Cheng HC; Wang JH; Fujita DJ
    Cell Growth Differ; 1995 Feb; 6(2):123-30. PubMed ID: 7538781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of new indole and bromoindole derivatives as pp60(c-Src) tyrosine kinase inhibitors.
    Kiliç Z; Işgör YG; Olgen S
    Chem Biol Drug Des; 2009 Oct; 74(4):397-404. PubMed ID: 19691468
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Attenuation of pressure-induced myogenic contraction and tyrosine phosphorylation by fasudil, a cerebral vasodilator, in rat cerebral artery.
    Masumoto N; Tanabe Y; Saito M; Nakayama K
    Br J Pharmacol; 2000 May; 130(2):219-30. PubMed ID: 10807658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new screening assay for allosteric inhibitors of cSrc.
    Simard JR; Klüter S; Grütter C; Getlik M; Rabiller M; Rode HB; Rauh D
    Nat Chem Biol; 2009 Jun; 5(6):394-6. PubMed ID: 19396179
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bio-recognition and functional lipidomics by glycosphingolipid transfer technology.
    Taki T
    Proc Jpn Acad Ser B Phys Biol Sci; 2013; 89(7):302-20. PubMed ID: 23883610
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of peptide ligands for targeting to the blood-brain barrier.
    van Rooy I; Cakir-Tascioglu S; Couraud PO; Romero IA; Weksler B; Storm G; Hennink WE; Schiffelers RM; Mastrobattista E
    Pharm Res; 2010 Apr; 27(4):673-82. PubMed ID: 20162339
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intracellular expression of Peptide fusions for demonstration of protein essentiality in bacteria.
    Benson RE; Gottlin EB; Christensen DJ; Hamilton PT
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2875-81. PubMed ID: 12936988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identifying diagnostic peptides for lyme disease through epitope discovery.
    Kouzmitcheva GA; Petrenko VA; Smith GP
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):150-60. PubMed ID: 11139210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.